abt 491 has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 6 studies
Studies (abt 491) | Trials (abt 491) | Recent Studies (post-2010) (abt 491) | Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) |
---|---|---|---|---|---|
9 | 0 | 5 | 9,156 | 187 | 552 |
Protein | Taxonomy | abt 491 (IC50) | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) |
---|---|---|---|
Platelet-activating factor receptor | Homo sapiens (human) | 0.0003 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Albert, DH; Carter, GW; Curtin, M; Davidsen, SK; Heyman, HR; Luo, G; Magoc, TJ; Morgan, DW; Sheppard, GS; Summers, JB; Tapang, P; Xu, L | 1 |
Albert, DH; Carter, GW; Curtin, ML; Davidsen, SK; Morgan, DW; Sheppard, GS; Summers, JB; Tapang, P | 1 |
Albert, DH; Carter, GW; Curtin, ML; Davidsen, SK; Malo, PE; Morgan, DW; Shaughnessy, TK; Sheppard, GS; Summers, JB; Tapang, P; Wegner, CD; Xu, L | 1 |
Atici, A; Bozlu, G; Nayci, A; Okuyaz, C; Polat, A; Taskinlar, H; Turhan, AH | 1 |
Gao, L; He, M; Ni, X; Sun, Y; Tang, G; Wang, L; Xu, B; Yu, Y | 1 |
Han, C; Li, L; Li, M; Liu, Y; Mao, Y; Song, S; Wang, Z; Xu, B; Yu, G; Zhou, L | 1 |
6 other study(ies) available for abt 491 and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Article | Year |
---|---|
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
Topics: Acute Disease; Animals; Blood Platelets; Dose-Response Relationship, Drug; Endotoxemia; Guinea Pigs; Humans; Imidazoles; Indoles; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; Neutrophils; Platelet Activating Factor; Platelet Membrane Glycoproteins; Rabbits; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Shock | 1997 |
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats.
Topics: Animals; Capillary Permeability; Imidazoles; Indoles; Kinetics; Nasal Mucosa; Platelet Activating Factor; Rats; Rats, Inbred BN; Rhinitis, Allergic, Perennial | 1997 |
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
Topics: Airway Resistance; Animals; Capillary Permeability; Guinea Pigs; Hypersensitivity; Imidazoles; Indoles; Male; Platelet Activating Factor; Rats; Rats, Inbred BN; Rhinitis | 1998 |
Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury.
Topics: Analysis of Variance; Animals; Animals, Newborn; Apoptosis; Caspase 3; Cell Count; Disease Models, Animal; Drug Administration Schedule; Hypoxia-Ischemia, Brain; Imidazoles; In Situ Nick-End Labeling; Indoles; Platelet Activating Factor; Rats | 2007 |
Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Androgen Receptor Antagonists; Androgens; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclofenil; Dihydrotestosterone; Disease Progression; Estradiol; Hormone Antagonists; Humans; Imidazoles; Indoles; Male; Mifepristone; Platelet Activating Factor; Prostatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Wnt Proteins | 2013 |
LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indoles; Male; Mice; Paclitaxel; PC-3 Cells; Platelet Activating Factor; Prostatic Neoplasms, Castration-Resistant; Up-Regulation | 2020 |